文献速递头颈与中枢神经肿瘤

奥那妥组单抗联合贝伐珠单抗对比安慰剂联合贝伐珠单抗治疗复发性胶质母细胞瘤的随机双盲安慰剂对照多中心II期研究:疗效、安全性及肝细胞生长因子和O6-甲基鸟嘌呤-DNA甲基转移酶生物标志物分析

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.
PubMed 文献 · J Clin Oncol · 2016-12-05

该II期研究在129例复发性胶质母细胞瘤患者中比较奥那妥组单抗联合贝伐珠单抗与安慰剂联合贝伐珠单抗,主要终点无进展生存期两组无显著差异(3.9个月 vs 2.9个月,HR 1.06,P=0.7444),总生存期亦无显著差异,探索性生物标志物分析提示肝细胞生长因子高表达或MGMT启动子未甲基化患者可能获益。

要点

  • 奥那妥组单抗联合贝伐珠单抗较安慰剂联合贝伐珠单抗未改善无进展生存期(3.9个月 vs 2.9个月,HR 1.06,P=0.7444)。
  • 总生存期两组无显著差异(8.8个月 vs 12.6个月,HR 1.45,P=0.1389)。
  • 探索性分析提示肝细胞生长因子高表达或MGMT启动子未甲基化患者可能从奥那妥组单抗联合贝伐珠单抗获益。

核心结论

  • 在未选择的复发性胶质母细胞瘤患者中,奥那妥组单抗联合贝伐珠单抗较安慰剂联合贝伐珠单抗未显示进一步临床获益。
  • 作者认为值得对生物标志物亚组进行进一步研究。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心II期研究GO27819。
  • 入组129例放化疗后首次复发、未接受过贝伐珠单抗的胶质母细胞瘤患者,按1:1随机分配至奥那妥组单抗联合贝伐珠单抗组(n=64)或安慰剂联合贝伐珠单抗组(n=65)。
  • 奥那妥组单抗15 mg/kg每3周一次联合贝伐珠单抗15 mg/kg每3周一次,或安慰剂联合贝伐珠单抗,直至疾病进展。
  • 主要终点为按神经肿瘤学反应评估标准的无进展生存期;次要终点为总生存期、客观缓解率、缓解持续时间和安全性。

主要发现

  • 中位无进展生存期奥那妥组单抗联合贝伐珠单抗组为3.9个月,安慰剂联合贝伐珠单抗组为2.9个月(HR 1.06;95%CI 0.72至1.56;P=0.7444)。
  • 中位总生存期奥那妥组单抗联合贝伐珠单抗组为8.8个月,安慰剂联合贝伐珠单抗组为12.6个月(HR 1.45;95%CI 0.88至2.37;P=0.1389)。
  • ≥3级不良事件在奥那妥组单抗联合贝伐珠单抗组发生率为38.5%,在安慰剂联合贝伐珠单抗组为35.9%。
  • 探索性生物标志物分析提示肝细胞生长因子高表达或O6-甲基鸟嘌呤-DNA甲基转移酶启动子未甲基化的患者可能从奥那妥组单抗联合贝伐珠单抗获益。

关键数值与推荐

  • 中位无进展生存期:奥那妥组单抗联合贝伐珠单抗组3.9个月 vs 安慰剂联合贝伐珠单抗组2.9个月(HR 1.06;95%CI 0.72至1.56;P=0.7444)。
  • 中位总生存期:奥那妥组单抗联合贝伐珠单抗组8.8个月 vs 安慰剂联合贝伐珠单抗组12.6个月(HR 1.45;95%CI 0.88至2.37;P=0.1389)。
  • ≥3级不良事件发生率:奥那妥组单抗联合贝伐珠单抗组38.5% vs 安慰剂联合贝伐珠单抗组35.9%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出,在未选择的患者中未观察到进一步临床获益,但值得对生物标志物亚组进行进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Bevacizumab regimens are approved for the treatment of recurrent glioblastoma in many countries. Aberrant mesenchymal-epithelial transition factor (MET) expression has been reported in glioblastoma and may contribute to bevacizumab resistance. The phase II study GO27819 investigated the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus bevacizumab (Pla + Bev) in recurrent glioblastoma. Methods At first recurrence after chemoradiation, bevacizumab-naïve patients with glioblastoma were randomly assigned 1:1 to receive Ona (15 mg/kg, once every 3 weeks) + Bev (15 mg/kg, once every 3 weeks) or Pla + Bev until disease progression. The primary end point was progression-free survival by response assessment in neuro-oncology criteria. Secondary end points were overall survival, objective response rate, duration of response, and safety. Exploratory biomarker analyses correlated efficacy with expression levels of MET ligand hepatocyte growth factor, O6-methylguanine-DNA methyltransferase promoter methylation, and glioblastoma subtype. Results Among 129 patients enrolled (Ona + Bev, n = 64; Pla + Bev, n = 65), baseline characteristics were balanced. The median progression-free survival was 3.9 months for Ona + Bev versus 2.9 months for Pla + Bev (hazard ratio, 1.06; 95% CI, 0.72 to 1.56; P = .7444). The median overall survival was 8.8 months for Ona + Bev and 12.6 months for Pla + Bev (hazard ratio, 1.45; 95% CI, 0.88 to 2.37; P = .1389). Grade ≥ 3 adverse events were reported in 38.5% of patients who received Ona + Bev and 35.9% of patients who received Pla + Bev. Exploratory biomarker analyses suggested that patients with high expression of hepatocyte growth factor or unmethylated O6-methylguanine-DNA methyltransferase may benefit from Ona + Bev. Conclusion There was no evidence of further clinical benefit with the addition of onartuzumab to bevacizumab compared with bevacizumab plus placebo in unselected patients with recurrent glioblastoma in this phase II study; however, further investigation into biomarker subgroups is warranted.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Cloughesy T, Finocchiaro G, Belda-Iniesta C, et al. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. J Clin Oncol. 2016. PMID: 27918718. doi:10.1200/JCO.2015.64.7685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。